Home » Stocks » SANA

Sana Biotechnology, Inc. (SANA)

Sana Biotechnology will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -215.18M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News
Puget Sound Business Journal - 5 days ago

The Seattle-based gene therapy startup filed with the U.S. Securities and Exchange Commission on Wednesday.

BioSpace - 5 days ago

Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the company's cell-based therapy dis...

GeekWire - 6 days ago

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest...

NASDAQ - 6 days ago

Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, filed on Wednesday with the SEC to raise up to $150 million in an initial public offering.

SEC - 6 days ago

Sana Biotechnology, Inc. has filed to go public with an IPO on the NASDAQ.

News-Medical.net - 1 week ago

UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue ...

About SANA

Sana Biotechnology was founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access t... [Read more...]

Industry
Biological Products
IPO Date
Pending
CEO
Steven D. Harr, M.D.
Employees
240
Stock Exchange
NASDAQ
Ticker Symbol
SANA
Full Company Profile

Financial Performance

Financial Statements